ABL to support US Army's medical product research and development programme


US-based contract research and manufacturing organisation ABL is to support the US Army's $900m medical product research and development (MPRD) programme.

Under a contract awarded by the US Army Medical Research and Materiel Command (MRMC), the company is to provide its comprehensive project management, product development, GMP manufacturing, and testing services for the MPRD project.

The contract has a five-year base period, and includes five additional one-year options.

ABL president and CEO Thomas VanCott said: "The required breadth of product development expertise for the scope of this contract lies within ABL's core competency.

"ABL provides a unique combination of scientific expertise coupled with operational excellence to address the complex medical issues facing our military today."

"With over 50 years of experience conducting biomedical research, as well as manufacturing vaccines and therapeutics for the US Government, ABL provides a unique combination of scientific expertise coupled with operational excellence to address the complex medical issues facing our military today.

"ABL has a proven track record of rapidly assessing highly technical projects and bringing together the right mix of in-house capabilities and external resources to complete mission objectives, and we look forward to contributing to the advancement of critical medical research and products required by the army and other US Department of Defense (DoD) entities."

The company is a member of the Engility Corporation team that recently won the contract to provide chemical, biological, radiological and nuclear (CBRN) support to US military services.